Elite Pharmaceuticals, Inc.
OTCPKELTP heads into the final day of April with its commercial debut fading from view and the stock quietly giving back ground — down nearly 6% on the week and 6.6% over the past month to $0.346. The big catalyst in this window was the early April launch of generic methadone hydrochloride tablets, the company's first commercial product following years of development-stage positioning…
Snapshot as of 10 May 2026
ELTP heads into the final day of April with its commercial debut fading from view and the stock quietly giving back ground — down nearly 6% on the week and 6.6% over the past month to $0.346. The big catalyst in this…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ELTP — free to start on ORTEX.
Sign up for free →Open ELTP on ORTEX